3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Recurrence
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, Large B-Cell, Diffuse
4
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Lymphoma, B-Cell
3
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
Plasmacytoma
1
Nasopharyngeal Carcinoma
1
Meningeal Carcinomatosis
1
Lymphoma
1
Liver Neoplasms
1
Leukemia
1
Glioma
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
pembrolizumab
4
atezolizumab
3
Cetuximab
3
olaparib
2
Trastuzumab
2
Docetaxel
2
zimberelimab
1
tocilizumab
1
spartalizumab
1
ribociclib
1
pralsetinib
1
pertuzumab
1
pegylated granulocyte colony-stimulating factor
1
ipatasertib
1
inavolisib
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
encorafenib
1
cemiplimab
1
binimetinib
1
anlotinib
1
amivantamab
1
alectinib
1
adagrasib
1
Pemetrexed
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Irinotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Solid Tumors
×
Immunotherapy, Adoptive
×
90 days
×
Clear all
No trials found.